-
serum level of Gal-1 is a novel risk factor for both gestational hypertension and preeclampsia, specifically its expression at a low level in the second trimester and a high level after onset.
-
Silencing Gal-1 impaired invasiveness, and decreased S1PR1 expression and overexpression in gastric cancer can promote the expression of S1PR1and invasion of gastric cancer cells.
-
Association of galectin-1 expression with eosinophilic infiltration of the tumor tissue in stomach and colorectal cancer was detected.
-
Study shows that recombinant Galectin-1 (Gal-1) could promote the differentiation and invasion of Trophoblast stem cells (TSCs), suggesting that some of Ishikawa cells secretion increase the expression of Gal-1 in TSCs during implantation, which then induced trophoblast differentiation and invasion in vitro.
-
In conclusion, these findings suggest that the serum levels of Gal-1, Gal-3, and Gal-9 may be associated with large artery atherosclerotic stroke.
-
High LGALS1 expression is associated with fibrosis in chronic pancreatitis and pancreatic cancer.
-
Pancreatic stellate cells promote cancer proliferation, migration, and invasion via Gal1-driven pathways. Gene-expression analyses of pancreatic tumor cells exposed to Gal1 reveal modulation of multiple regulatory pathways involved in tumor progression.
-
Studies indicate tumor-derived galectin-1, galectin-3 and galectin-9 in various cancers and anticancer therapies that target these molecules [Review].
-
The expression level of galectin-1 affects survival in patients with glioblastoma multiforme treated with adjuvant radiotherapy
-
Results show that Galectin-1 teams up with Galectin-3 to induce inflammatory/pro-degradative gene signature in human chondrocytes affecting the progression of osteoarthritis. Also, Galectin-3 was found to induce a pro-degradative-inflammatory gene signature in human chondrocytes, teaming up with Galectin-1 in the pathogenesis of osteoarthritis.
-
We also found a subset of prostate cancer patient-derived xenografts and prostate cancer patient samples with mild HO-1 and low Gal-1 expression levels. These results highlight a novel function of a human-used drug as a means of boosting the antitumor response
-
Gal-1, Gal-3 and Gal-9 galectin expression was higher in the myenteric plexus ganglia of chagasic patients
-
Results have shown that Gal-1 in the farnesyl-bound form acquires the ability to form self-clusters, and the galactoside-binding pocket of Gal-1 in the FTS-bound form plays an important role in self-cluster formation.
-
Our findings support the introduction of galectin-1 as a reliable diagnostic marker for thyroid carcinomas. Its involvement in cell proliferation, migration, invasion and tumor growth also intimate functional involvement of galectin-1 in the progression of thyroid carcinoma, suggesting its potential as a therapeutic target
-
This study showed that obese children had significantly higher galectin-1 levels in proportion to fat mass in obese cases than those in healthy children, which may be interpreted as a compensatory increase in an attempt to improve glucose metabolism.
-
We further demonstrated using the NMR-based hydrogen-deuterium exchange (HDX) that lactose binding increases the exchange rates of residues located on the opposite side of the ligand-binding pocket for hGal1 and hGal8(NTD), indicative of allostery. Additionally, lactose binding induces significant stabilisation of hGal8(CTD) across the entire domain
-
our findings indicate that galectin-1 plays a pivotal role in the regulation of key processes in cancer cells, such as migration, invasion, and chemoresistance, by modulating FAK and ERK signaling and survivin level.
-
Gal-3 staining in the nucleus could be a new positive prognosticator for ovarian cancer.
-
Gal-1 may offer an additional therapeutic target linking anti-angiogenesis and immune checkpoint blockade.
-
markedly increased brain Gal-1 and S-nitrosylated Gal-1 both in scrapie-infected rodents and human prion diseases.
